SEC Tracker
Get the app

Oragenics OGEN

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Form
8-K
Filed
Period
Importance
Routine
Document
8-K
Exhibit 99.1
Press release
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Oragenics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Inhibitor Therapeutics INTI public float $3M, Jun 30, 2025
  2. PTC Therapeutics PTCT public float $3M, Jun 30, 2025
  3. Integrated Biopharma INBP public float $3M, Dec 31, 2025
  4. Enveric Biosciences ENVB public float $4M, Jun 30, 2025
  5. Polomar Health Services PMHS public float $4M, Jun 30, 2025